Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PEP-DC
- Development stage
- Phase 2
- Lead developer
- Centre Hospitalier Universitaire Vaudois
- Modality
- Vaccines & Immunotherapeutics, Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies
- Administration
- Subcutaneous
01
Overview
PEP-DC is an autologous dendritic cell (DC) vaccine loaded with personalized peptides, designed as a therapeutic cancer vaccine. The approach involves isolating monocyte-derived dendritic cells from the patient, pulsing them with a set of personalized tumor-associated peptides (PEP), and then administering these cells back to the patient as a subcutaneous injection. The goal is to stimulate the patient's immune system to recognize and attack cancer cells expressing those specific antigens. In clinical studies, PEP-DC has been evaluated in combination with low-dose cyclophosphamide for patients with advanced or recurrent metastatic non-small cell lung cancer (NSCLC)[6].
- Other names
- PEP-DC vaccine
02
Targets
TCR (T cell antigen receptor complex)Hla (Staphylococcus aureus alpha toxin)
Beyond the preview
Go deeper on PEP-DC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PEP-DC.